

Roberta Gagliardini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5435259/publications.pdf>

Version: 2024-02-01

24
papers

378
citations

758635

12
h-index

794141

19
g-index

24
all docs

24
docs citations

24
times ranked

748
citing authors

#	ARTICLE	IF	CITATIONS
1	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18
2	Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study. <i>Journal of Global Antimicrobial Resistance</i> , 2022, , .	0.9	2
3	Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 30, 326-334.	0.9	6
4	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106252.	1.1	13
5	Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. <i>International Journal of Infectious Diseases</i> , 2021, 105, 532-539.	1.5	20
6	Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 108, 244-251.	1.5	29
7	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of na ⁺ ve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106406.	1.1	4
8	Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers. <i>Biology of Sex Differences</i> , 2021, 12, 63.	1.8	10
9	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected na ⁺ ve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , 2019, 169, 104552.	1.9	23
10	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , 2019, 19, 59.	1.3	23
11	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019, 47, 589-593.	2.3	4
12	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e17-e21.	0.9	2
13	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. <i>Antiviral Therapy</i> , 2018, 23, 139-148.	0.6	9
14	HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. <i>Journal of Clinical Virology</i> , 2018, 103, 57-62.	1.6	3
15	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	1.3	29
16	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy113.	0.4	56
17	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	1.3	28
18	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017, 29, 299-307.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS ONE, 2017, 12, e0187393.	1.1	11
20	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). Clinical Neuropsychologist, 2016, 30, 1457-1468.	1.5	19
21	Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-term all-cause mortality: a MASTER cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3519-3527.	1.3	16
22	Liver fibrosis progression and clinical outcomes are intertwined. Medicine (United States), 2016, 95, e4091.	0.4	17
23	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infectious Diseases, 2015, 2, ofv043.	0.4	30
24	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. Journal of Infection, 2014, 68, 500-503.	1.7	1